Cargando…

Epigenetic modulators as therapeutic targets in prostate cancer

Prostate cancer is one of the most common non-cutaneous malignancies among men worldwide. Epigenetic aberrations, including changes in DNA methylation patterns and/or histone modifications, are key drivers of prostate carcinogenesis. These epigenetic defects might be due to deregulated function and/...

Descripción completa

Detalles Bibliográficos
Autores principales:	Graça, Inês, Pereira-Silva, Eva, Henrique, Rui, Packham, Graham, Crabb, Simon J., Jerónimo, Carmen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5025578/ https://www.ncbi.nlm.nih.gov/pubmed/27651838 http://dx.doi.org/10.1186/s13148-016-0264-8

Ejemplares similares

A multiplatform approach identifies miR-152-3p as a common epigenetically regulated onco-suppressor in prostate cancer targeting TMEM97
por: Ramalho-Carvalho, João, et al.
Publicado: (2018)

Metabolism and Epigenetic Interplay in Cancer: Regulation and Putative Therapeutic Targets
por: Miranda-Gonçalves, Vera, et al.
Publicado: (2018)

Epigenetic Markers for Molecular Detection of Prostate Cancer
por: Costa, Vera L., et al.
Publicado: (2007)

Corrigendum: Metabolism and Epigenetic Interplay in Cancer: Regulation and Putative Therapeutic Targets
por: Miranda-Gonçalves, Vera, et al.
Publicado: (2019)

Vacuolar ATPase as a potential therapeutic target and mediator of treatment resistance in cancer
por: Whitton, Bradleigh, et al.
Publicado: (2018)

From Therapy Resistance to Targeted Therapies in Prostate Cancer
por: Moreira-Silva, Filipa, et al.
Publicado: (2022)

Targeting DNA Methyltranferases in Urological Tumors
por: Marques-Magalhães, Ângela, et al.
Publicado: (2018)

Targeting the Immune system and Epigenetic Landscape of Urological Tumors
por: Lobo, João, et al.
Publicado: (2020)

Histone methyltransferase PRMT6 plays an oncogenic role of in prostate cancer
por: Almeida-Rios, Diogo, et al.
Publicado: (2016)

Downregulation of miR-130b~301b cluster is mediated by aberrant promoter methylation and impairs cellular senescence in prostate cancer
por: Ramalho-Carvalho, João, et al.
Publicado: (2017)

Epigenetic modulation and prostate cancer: Paving the way for NK cell anti-tumor immunity
por: dos Reis, Filipa D., et al.
Publicado: (2023)

Anti-neoplastic properties of hydralazine in prostate cancer
por: Graça, Inês, et al.
Publicado: (2014)

Novel Insights on the Role of Epigenetics in Androgen Receptor’s Expression in Prostate Cancer
por: Camilo, Vânia, et al.
Publicado: (2023)

Epigenetic mechanisms underlying prostate cancer radioresistance
por: Macedo-Silva, Catarina, et al.
Publicado: (2021)

Integrative epigenetic taxonomy of primary prostate cancer
por: Stelloo, Suzan, et al.
Publicado: (2018)

DNA Methylation as a Therapeutic Target for Bladder Cancer
por: Nunes, Sandra P., et al.
Publicado: (2020)

The Critical Role of Hypoxic Microenvironment and Epigenetic Deregulation in Esophageal Cancer Radioresistance
por: Macedo-Silva, Catarina, et al.
Publicado: (2019)

Epigenetic regulation of MDR1 gene through post-translational histone modifications in prostate cancer
por: Henrique, Rui, et al.
Publicado: (2013)

The Epigenetics of Renal Cell Tumors: from Biology to Biomarkers
por: Henrique, Rui, et al.
Publicado: (2012)

Epigenetic Mechanisms Influencing Epithelial to Mesenchymal Transition in Bladder Cancer
por: Monteiro-Reis, Sara, et al.
Publicado: (2019)

Epigenetic Alterations in Oesophageal Cancer: Expression and Role of the Involved Enzymes
por: Lopes, Nair, et al.
Publicado: (2020)

Regulation of histone H2A.Z expression is mediated by sirtuin 1 in prostate cancer
por: Baptista, Tiago, et al.
Publicado: (2013)

Analysis of Epigenetic Alterations in Homologous Recombination DNA Repair Genes in Male Breast Cancer
por: André, Saudade, et al.
Publicado: (2020)

SMYD3 contributes to a more aggressive phenotype of prostate cancer and targets Cyclin D2 through H4K20me3
por: Vieira, Filipa Quintela, et al.
Publicado: (2015)

Repurposing Old Drugs into New Epigenetic Inhibitors: Promising Candidates for Cancer Treatment?
por: Moreira-Silva, Filipa, et al.
Publicado: (2020)

Altered Expression of MGMT in High-Grade Gliomas Results from the Combined Effect of Epigenetic and Genetic Aberrations
por: Ramalho-Carvalho, João, et al.
Publicado: (2013)

Editorial: Epigenetic insights into diagnostic and therapeutic applications
por: Fratta, Elisabetta, et al.
Publicado: (2023)

Epigenetic regulation of EFEMP1 in prostate cancer: biological relevance and clinical potential
por: Almeida, Mafalda, et al.
Publicado: (2014)

The Complex Interplay between Metabolic Reprogramming and Epigenetic Alterations in Renal Cell Carcinoma
por: Lameirinhas, Ana, et al.
Publicado: (2019)

Histone variant MacroH2A1 is downregulated in prostate cancer and influences malignant cell phenotype
por: Vieira-Silva, Tânia Soraia, et al.
Publicado: (2019)

Tackling tumor microenvironment through epigenetic tools to improve cancer immunotherapy
por: Lodewijk, Iris, et al.
Publicado: (2021)

MicroRNA-27a-5p regulation by promoter methylation and MYC signaling in prostate carcinogenesis
por: Barros-Silva, Daniela, et al.
Publicado: (2018)

Human Germ Cell Tumors are Developmental Cancers: Impact of Epigenetics on Pathobiology and Clinic
por: Lobo, João, et al.
Publicado: (2019)

Uncovering potential downstream targets of oncogenic GRPR overexpression in prostate carcinomas harboring ETS rearrangements
por: Santos, Joana, et al.
Publicado: (2015)

Flavonoids as Epigenetic Modulators for Prostate Cancer Prevention
por: Izzo, Simona, et al.
Publicado: (2020)

Epigenetic Modulators as Therapeutic Agents in Cancer
por: Patnaik, Eshaan, et al.
Publicado: (2023)

Epigenetics as a Therapeutic Target in Osteoarthritis
por: Núñez-Carro, Carmen, et al.
Publicado: (2023)

Epigenetic regulation of TP53 is involved in prostate cancer radioresistance and DNA damage response signaling
por: Macedo-Silva, Catarina, et al.
Publicado: (2023)

Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential?
por: Nolan, L, et al.
Publicado: (2008)

Hydralazine and Panobinostat Attenuate Malignant Properties of Prostate Cancer Cell Lines
por: Pacheco, Mariana Brütt, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_d4r72pbki1231m9nlr1u1dhmmk